CA3218187A1 - Fc mutant with altered binding to fc receptor - Google Patents

Fc mutant with altered binding to fc receptor Download PDF

Info

Publication number
CA3218187A1
CA3218187A1 CA3218187A CA3218187A CA3218187A1 CA 3218187 A1 CA3218187 A1 CA 3218187A1 CA 3218187 A CA3218187 A CA 3218187A CA 3218187 A CA3218187 A CA 3218187A CA 3218187 A1 CA3218187 A1 CA 3218187A1
Authority
CA
Canada
Prior art keywords
sequence
seq
amino acid
set forth
chain set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218187A
Other languages
English (en)
French (fr)
Inventor
Fenggen FU
Shuaixiang ZHOU
Zhihai WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of CA3218187A1 publication Critical patent/CA3218187A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3218187A 2021-05-07 2022-05-06 Fc mutant with altered binding to fc receptor Pending CA3218187A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN202110495363.7 2021-05-07
CN202210436873 2022-04-25
CN202210436873.1 2022-04-25
PCT/CN2022/091187 WO2022233320A1 (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Publications (1)

Publication Number Publication Date
CA3218187A1 true CA3218187A1 (en) 2022-11-10

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218187A Pending CA3218187A1 (en) 2021-05-07 2022-05-06 Fc mutant with altered binding to fc receptor

Country Status (8)

Country Link
US (1) US20240228579A1 (cg-RX-API-DMAC7.html)
EP (1) EP4335868A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516320A (cg-RX-API-DMAC7.html)
CN (1) CN117295760A (cg-RX-API-DMAC7.html)
AU (1) AU2022269145B2 (cg-RX-API-DMAC7.html)
CA (1) CA3218187A1 (cg-RX-API-DMAC7.html)
TW (1) TWI839729B (cg-RX-API-DMAC7.html)
WO (1) WO2022233320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024333211A1 (en) * 2023-08-30 2026-03-19 Astellas Pharma Inc. Fc REGION VARIANT

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP3342782B1 (en) * 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
ES2597228T3 (es) * 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US12024560B2 (en) * 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Also Published As

Publication number Publication date
WO2022233320A1 (zh) 2022-11-10
AU2022269145A1 (en) 2023-12-21
TWI839729B (zh) 2024-04-21
TW202246313A (zh) 2022-12-01
EP4335868A4 (en) 2025-08-13
US20240228579A1 (en) 2024-07-11
EP4335868A1 (en) 2024-03-13
JP2024516320A (ja) 2024-04-12
AU2022269145B2 (en) 2026-05-28
CN117295760A (zh) 2023-12-26

Similar Documents

Publication Publication Date Title
JP7403505B2 (ja) Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
JP6994942B2 (ja) T細胞再標的化ヘテロ二量体免疫グロブリン
CA2810465C (en) Anti-hutnfr1 antibody
KR20150076172A (ko) 이질-이합체 면역글로불린의 정제
WO2017186908A1 (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
JP7842914B2 (ja) C5aRを標的とする抗体
CN120530132A (zh) 结合白介素4受体α的抗体和使用方法
TWI724393B (zh) 抗糖皮質激素誘導的腫瘤壞死因子受體(gitr)的小型化抗體、其聚合物及應用
JP2026514143A (ja) Ox40lに結合する抗体及びその使用方法
WO2021064152A1 (en) Hybrid antibody
EP4335868A1 (en) Fc mutant with altered binding to fc receptor
TW202607021A (zh) 結合tslp之抗體及使用方法
US20250059288A1 (en) Antibodies targeting ccr2
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
KR20260007638A (ko) Cd3을 표적으로 하는 항체 또는 이의 항원 결합 단편 및 이의 용도
WO2025125545A1 (en) Effectorless igg1 fc variants
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
HK40061359A (en) Antibodies targeting c5ar

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250414

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260504

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260504

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260511

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260511